Cytogenetics of Childhood Acute Myeloid Leukemia: United Kingdom Medical Research Council Treatment Trials AML 10 and 12

Christine J. Harrison(Newcastle University), Brenda Gibson(Royal Hospital for Children), Anthony V. Moorman(Blood Cancer UK), Robert K. Hills(Cancer Research UK Clinical Trials Unit), David Grimwade(University of Cambridge), David Webb(Royal Hospital for Children), Ian Hann(Royal Hospital for Children), Siebold S.N. de Graaf(Royal Hospital for Children), Alan K. Burnett(Cardiff University), Eva van den Berg(Royal Hospital for Children), Keith Wheatley(Cancer Research UK Clinical Trials Unit)
Journal of Clinical Oncology
May 4, 2010
10.1200/jco.2009.24.8997
Cited by 305

Related Papers

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
|Blood|2009|3.4k
The Importance of Diagnostic Cytogenetics on Outcome in AML: Analysis of 1,612 Patients Entered Into the MRC AML 10 Trial
|Blood|1998|2.6k
Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials
|Blood|2010|1.9k
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2018|1k